General information about company

Scrip code*543213
NSE Symbol*ROSSARI
MSEI Symbol*NOTLISTED
ISIN*INE02A801020
Name of companyROSSARI BIOTECH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved17-01-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange09-01-2026
Description of presentation currencyINR
Level of roundingMillions
Reporting TypeQuarterly
Reporting QuarterThird quarter
Nature of report standalone or consolidatedConsolidated
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingSingle segment
Description of single segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries
Start date and time of board meeting17-01-2026 12:30
End date and time of board meeting17-01-2026 13:30
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations5816.817115.03
Other income5.0933.13
Total income5821.8917148.16
2Expenses
(a)Cost of materials consumed4175.9911592.1
(b)Purchases of stock-in-trade109.73693.18
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-277.71-555.24
(d)Employee benefit expense 402.561155.2
(e)Finance costs76.65194.84
(f)Depreciation, depletion and amortisation expense196.14555.96
(g)Other Expenses
1Other Expenses717.52143.27
Total other expenses717.52143.27
Total expenses5400.8615779.31
3Total profit before exceptional items and tax421.031368.85
4Exceptional items 00
5Total profit before tax421.031368.85
6Tax expense
7Current tax132.08453.64
8Deferred tax-34.81-103.38
9Total tax expenses97.27350.26
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations323.761018.59
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method3.9813.87
16Total profit (loss) for period327.741032.46
17Other comprehensive income net of taxes-1.74-5.44
18Total Comprehensive Income for the period3261027.02
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent327.741032.46
Total profit or loss, attributable to non-controlling interests00
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent-1.74-5.44
Total comprehensive income for the period attributable to owners of parent non-controlling interests00
21Details of equity share capital
Paid-up equity share capital110.76110.76
Face value of equity share capital00
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations5.9218.65
Diluted earnings (loss) per share from continuing operations5.9118.63
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations5.9218.65
Diluted earnings (loss) per share from continuing and discontinued operations5.9118.63
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 17th January,2026.2.The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) 34 on "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.3.The consolidated financial results include the financial results of four foreign subsidiaries - Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited and Rossari (Singapore) Pte Ltd (incorporated on 18th December 2025) two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd., (100% subsidiary of Rossari Global DMCC), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).4.The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.5.During the quarter ended 31st December, 2025, the Company has allotted 14,400 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.6."The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the ‘New Labour Codes’). These codes have been made effective from 21st November, 2025.The Group has estimated the revised gratuity liability as at 31st December 2025 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expense in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes.The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified."7.Previous year/period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material.
For ROSSARI BIOTECH LIMITED
SUNIL CHARI
Managing Director
DIN:00149083
Place : Mumbai
Date :17th January,2026



Other Comprehensive Income

Date of start of reporting period01-10-202501-04-2025
Date of end of reporting period31-12-202531-12-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Remeasurements of the defined benefit plans-2.87-9.38
Total Amount of items that will not be reclassified to profit and loss-2.87-9.38
2Income tax relating to items that will not be reclassified to profit or loss -0.72-2.36
3Amount of items that will be reclassified to profit and loss
1Exchange on translation of foreign operations0.942.11
2Income tax relating to items that will be reclassified to profit or loss -0.53-0.53
Total Amount of items that will be reclassified to profit and loss0.411.58
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income-1.74-5.44